Testing Part B Payment Cuts: Sequester Means Providers Get ASP+4%
This article was originally published in RPM Report
Cutting the payment level for Medicare Part B drugs is a perennial budget proposal, but never gets very far in Congress. Now, thanks to the sequester, Part B payments have been cut from ASP+6% to ASP+4.3%. Will it stick?
You may also be interested in...
Remember what happened the last time physician groups opposed federal efforts to curtail Medicare spending on Part B drugs?
Fears that sequestration cuts to Medicare Part B drug payments would lead to drug access issues have failed to materialize, CMS’ Jonathan Blum tells the FDA/CMS Summit.
Two large pharmaceutical manufacturers weigh in on whether the sequester is impacting their injectables business. The answer so far: not really. The same story goes for the sequester and Part D, though Lilly is seeing higher than expected Part D discounts in 2013.